Eplerenone reduces oxidative stress and enhances eNOS in SHR: Vascular functional and structural consequences

Antioxidants and Redox Signaling

Volumn 7, Issue 9-10, 2005, Pages 1294-1301

  Sanz Rosa, David ^a   Oubiña, M Pilar ^a   Cediel, Eva ^a   De Las Heras, Natalia ^a   Aragoncillo, Paloma ^b   Balfagón, Gloria ^c   Cachofeiro, Victoria ^a   Lahera, Vicente ^a,d  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; COMPLEMENTARY DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; GLUTATHIONE; MALONALDEHYDE; MESSENGER RNA; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HYPERTENSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM; VASCULAR RING;

ACETYLCHOLINE; ALDOSTERONE; ANIMALS; AORTA; BODY WEIGHT; ENDOTHELIUM, VASCULAR; GLUTATHIONE; HEMODYNAMIC PROCESSES; LIVER; MALE; MALONDIALDEHYDE; MEMBRANE TRANSPORT PROTEINS; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ALDOSTERONE; RNA, MESSENGER; SPIRONOLACTONE; SYSTOLE;

EID: 24144490658     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1294     Document Type: Article

References (47)

1. Alexander MY, Brosnan MJ, Hamilton CA, Downie P, Devlin AM, Dowell F, Martin W, Prentice HM, O'Brien T, and Dominiczak AF. Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model. Cardiovasc Res 43: 798-807, 1999.
2. Brown NJ. Eplerenone: cardiovascular protection. Circulation 107: 2512-2518, 2003.
3. Carbonell LF, Nadal JA, Llanos C, Hernandez I, Nava E, and Diaz J. Depletion of liver glutathioue potentiates the oxidative stress and decreases nitric oxide synthesis in a rat endotoxin shock model. Crit Care Med 28: 2002-2006, 2000.
4. Cediel E, Sanz-Rosa D, Oubina MP, De Las Heras N, Gonzalez Pacheco FR, Vegazo O, Jimenez J, Cachofeiro V, and Lahera V. Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regul Integr Comp Physiol 285: R674-R681, 2003.
5. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15: 532-534, 536-537, 1993.
6. Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, and Lentz SR. Deficiency of glutathione peroxidase-1 sensitizes to endothelial dysfunction in hyperhomocysteinemic mice. Arterioscler Thromb Vasc Biol 22: A29-A30, 2002.
7. Duprez D, De Buyzere M, Rietzschel ER, and Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2: 327-334, 2000.
8. Farquharson CA and Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101: 594-597, 2000.
9. Farquharson CA and Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103: 425-431, 2002.
10. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, and Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol 282: H1255-H1261, 2002.
11. Funder JW. Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens 10: 227-230, 2001.
12. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 79(5A): 3-8, 1997.
13. Giebisch G and Wang W. Renal tubule potassium channels: function, regulation and structure. Acta Physiol Scand 170: 153-173, 2000.
14. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, and Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Ear J Pharmacol 290: 69-73, 1995.
15. Kaplowitz N, Aw TY, and Ookhtens M. The regulation of hepatic glutathione. Annu Rev Pharmacol Toxicol 25: 715-744, 1985.
16. Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. Altern Med Rev 2: 155-176, 1997.
17. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, and Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40: 117-123, 2002.
18. las Heras N, Aragoncillo P, Maeso R, Vazquez-Perez S, Navarro-Cid J, DeGasparo M, Mann J, Ruilope LM, Cachofeiro V, and Lahera V. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 34: 969-975, 1999.
19. Lim PO, Struthers AD, and MacDonald TM. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens 20: 11-15, 2002.
20. Lou YK, Wen C, Li M, Adams DJ, Wang MX, Yang F, Morris BJ, and Whitworth JA. Decreased renal expression of nitric oxide synthase isoforms in adrenocorticotropin-induced and corticosterone-induced hypertension. Hypertension 31: 1164-1170, 2001.
21. Maeso R, Rodrigo E, Munoz-Garcia R, Navarro-Cid J, Ruilope LM, Cachofeiro V, and Lahera V. Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. J Hypertens 16: 665-672, 1998.
22. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H, and Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32: 3-8, 1998.
23. Mombouli JV and Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 31: 61-74, 1999.
24. Moreno C, Lopez A, Llinas MT, Rodriguez F, Lopez-Farre Nava A, and Salazar FJ. Changes in NOS activity and protein expression during acute and prolonged angiotensin II administration. Am J Physiol Regul Integr Comp Physiol 282: R31-R37, 2002.
25. Munzel T, Heitzer T, and Harrison DG. The physiology and pathophysiology of the nitric oxide superoxide system. Herz 22: 158-172, 1997.
26. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, and Inoue M. Does Superoxide underlie the pathogenesis of hypertension? Proc Nat Acad Sci U S A 22: 158-172, 1997.
27. Palmer LG. Potassium secretion and the regulation of distal nephron K channels. Am J Physiol 277(6 Pt 2): F821-F825, 1999.
28. Palmer LG and Frindt G. Aldosterone and potassium secretion by the cortical collecting duct. Kidney Int 51: 1324-1328, 2000.
29. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, and Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential-hypertension- evidence that nitric-oxide abnormality is not localized to a single signal-transduction pathway. Circulation 91: 1732-1738, 1995.
30. Park JB and Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 31: 1444-1449, 2001.
31. Quaschning T, Ruschitzka F, Shaw S, and Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37(2 Part 2): 801-805, 2001.
32. Rajagopalan S, Duquaine D, King S, Pitt B, and Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212-2216, 2002.
33. Rocha R and Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 970: 89-100, 2002.
34. Rocha R and Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12: 308-314, 2001.
35. Rodrigo E, Maeso R, Munoz-Garcia R, Navarro-Cid J, Ruilope LM, Cachofeiro V, and Lahera V. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J Hypertens 15: 613-618, 1997.
36. Safar ME, London GM, Asmar R, and Frohlich ED. Recent advances on large arteries in hypertension. Hypertension 32: 156-161, 1998.
37. Stier CT Jr, Chander PN, and Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10: 97-107, 2002.
38. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J 144(5 Suppl): S2-S7, 2002.
39. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 8: 18-22, 2002.
40. Struthers AD and MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61: 663-670, 2004.
41. Taddei S, Virdis A, Mattei P, and Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21(6 Pt 2): 929-933, 1993.
42. Ullian ME, Walsh LG, and Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 32: 266-273, 1996.
43. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, and Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40: 504-510, 2002.
44. Ward MR, Kanellakis P, Ramsey D, Funder J, and Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104: 467-472, 2001.
45. Wickman A, Andersson IJL, Jia J, Hedin L, and Bergstrom G. Endothelial nitric oxide synthase protein is reduced in the renal medulla of two-kidney, one-clip hypertensive rats. J Hypertens 19: 1665-1673, 2001.
46. Young MJ and Funder JW. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J Hypertens 20: 1465-1468, 2002.
47. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 74: 139-162, 1994.